Becton, Dickinson and Co. | BDX - Fremdkapital

Aktienkurs
145.31
Täglich Wechseln
-4.21 -2.82%
Monatlich
-6.06%
Jährlich
-29.83%
Q2 Prognose
148.88




Fremdkapital Veränderung Datum
Abbott USD 29.64B 19.74B 2026-03
Agilent USD 3.05B 0 2025-12
Align Technology USD 0 0 2024-12
AngioDynamics USD 5.6M 100K 2025-09
Avanos Medical USD 90.3M 3.1M 2025-12
Baxter International USD 9.47B 726M 2025-12
Becton, Dickinson and Co. USD 16.92B 705M 2025-12
Bio-Rad Laboratories USD 1.2B 300K 2025-12
Boston Scientific USD 11.01B 19M 2025-12
Cooper Companies USD 1.88B 578.5M 2025-12
Danaher USD 17.56B 855M 2026-03
Dentsply International USD 2.02B 2M 2025-12
Dexcom USD 1.24B 53.6M 2025-12
Edwards Lifesciences USD 600M 1.7M 2026-03
Globus Medical USD 436K 9K 2025-12
Insulet USD 930.8M 4.1M 2025-12
Integra LifeSciences USD 1.86B 63.76M 2025-12
Intuitive Surgical USD 0 0 2025-03
J&J USD 37.53B 1.91B 2026-03
Masimo USD 518M 41.1M 2025-12
Medtronic USD 27.88B 255M 2025-12
Solventum Corp USD 5.04B 102M 2025-12
Stryker USD 14.86B 14M 2025-12
Tandem Diabetes Care USD 310.04M 446K 2025-12
Teleflex USD 2.54B 30.06M 2025-12
Terumo JPY 99.9B 12M 2025-12
Thermo Fisher Scientific USD 40.07B 4.22B 2026-03
Zimmer Biomet Holdings USD 6.3B 636.9M 2026-03